Clene Inc
Clinical stage biopharmaceutical firm focused on developing treatments for neurodegenerative diseases
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Clene Inc's stock with a target price of $111.75, indicating strong potential growth.
Financial Health
Clene Inc has modest revenue and strong profit margins, but cash flow remains a concern.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CLNN
Hope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Published: June 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Milestones Ahead
Trial readouts and regulatory milestones can meaningfully affect value, though outcomes are uncertain and may increase volatility.
R&D-Driven Value
The company’s prospects hinge on science and trial results; strong data can create opportunities, but development is costly and risky.
Liquidity & Funding
As a small‑cap, cash runway and access to capital matter; funding news can shift the share price materially—consider suitability for your portfolio.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
